Participants in both MV140 groups experienced fewer UTI episodes than the placebo group (P<0.001)
Both MV140 groups: median 0.0 (IQR, 0.0 to 1.0) episodes
Placebo: 3.0 (IQR, 0.5 to 6.0) episodes
Free from UTI at end of study period
Placebo: 25% (95% CI, 15 to 35%)
3-month MV140: 56% (95% CI, 44 to 67%)
6-month MV140: 58% (95% CI, 44 to 67%)
Hazard ratios (HR) for UTI vs placebo
3-month MV140: 0.36 (95% CI, 0.23 to 0.56)
6-month MV140: 0.33 (95% CI, 0.21 to 0.54)
Total of 205 events in 101 participants
Placebo: 81 events
3-month MV140: 76 events
6-month MV140: 48 events
Most common AEs (≥5% of participants)
Chest infection | Candidiasis | Vaginitis
In this clinical trial, MV140 was effective at reducing recurrent UTI in women
There did not appear to be a difference between a 3- or 6-month course of therapy
There were no significant adverse events
It is not well understood how the therapy works but MV140 appears to induce an adaptive antibody response
The authors state
…our current trial confirms that MV140 conferred durable protection for at least 1 year
The longer clinical benefits of MV140 once treatment is completed differ from management of recurrent UTI with antibiotic prophylaxis, which shows a rapid lack of efficacy following discontinuation as well as numerous side effects
OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Jointly provided by
NOT ENOUGH CME HOURS
It appears you don't have enough CME Hours to take this Post-Test. Feel free to buy additional CME hours or upgrade your current CME subscription plan